Skip to main content
Top
Published in: Clinical and Translational Oncology 11/2014

01-11-2014 | Brief Research Article

Genetic disorders of pediatric MEN2A patients in the south of Spain

Authors: Y. Martinez-Criado, R. M. Fernandez, S. Borrego, R. Cabello, I. Fernandez-Pineda

Published in: Clinical and Translational Oncology | Issue 11/2014

Login to get access

Abstract

Introduction

Medullary thyroid carcinoma (MTC) is observed in nearly 100 % of patients with multiple endocrine neoplasia type 2A (MEN2A). The gene responsible for MEN2A is the RET proto-oncogene and about 95 % of MEN2A patients have germline mutations in five specific cysteine codons (609, 611, 618, 620 and 634).

Materials and methods

A retrospective study of children from families with MEN2A in our geographic area was performed. Variables analyzed included demographic data, kinship relations, age at genetic screening, age at prophylactic thyroidectomy, genetic mutation subtype and histological findings. The genetic study consisted in direct molecular analysis by automatic sequencing of RET mutated exon in the studied family.

Results

We performed 13 prophylactic total thyroidectomies from 1997 to 2013, 8 females and 5 males. The mean age at genetic diagnosis was 3.8 years (range 2–5.9). All children belonged to four interconnected families living in the same geographic area and presenting C634Y mutation in all the cases. The mean age at prophylactic thyroidectomy was 5.6 years (range 4–8.5). Histopathological findings demonstrated seven cases of C-cells nodular hyperplasia, one lymphocytic thyroiditis, two without evidence of disease, two micro-carcinomas and one multicentric carcinoma.

Conclusion

The mutation found in the RET proto-oncogene responsible for MEN2A in pediatric patients in the south of Spain is the C635Y. It is considered a high-risk mutation, associated with an earlier malignant transformation and development of MTC.
Literature
1.
go back to reference Frank-Raue K, Rondot S, Raue F. Molecular genetics and phenomics of RET mutations: impact on prognosis of MTC. Mol Cell Endocrinol. 2010;322(1–2):2–7.PubMedCrossRef Frank-Raue K, Rondot S, Raue F. Molecular genetics and phenomics of RET mutations: impact on prognosis of MTC. Mol Cell Endocrinol. 2010;322(1–2):2–7.PubMedCrossRef
3.
go back to reference Wells SA Jr, Pacini F, Robinson BG, Santoro M. Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update. J Clin Endocrinol Metab. 2013;98:3149–64.PubMedCrossRef Wells SA Jr, Pacini F, Robinson BG, Santoro M. Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update. J Clin Endocrinol Metab. 2013;98:3149–64.PubMedCrossRef
4.
go back to reference Asai N, Iwashita T, Matsuyama M, Takahashi M. Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations. Mol Cell Biol. 1995;15:1613–9.PubMedPubMedCentral Asai N, Iwashita T, Matsuyama M, Takahashi M. Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations. Mol Cell Biol. 1995;15:1613–9.PubMedPubMedCentral
6.
go back to reference Sim Y, Yap F, Soo KC, Low Y. Medullary thyroid carcinoma in ethnic Chinese with MEN2A: a case report and literature review. J Pediatr Surg. 2013;48:43–6.CrossRef Sim Y, Yap F, Soo KC, Low Y. Medullary thyroid carcinoma in ethnic Chinese with MEN2A: a case report and literature review. J Pediatr Surg. 2013;48:43–6.CrossRef
7.
go back to reference Sánchez B, Antiñolo G, Navarro E, Japón MA, Conde AF, Astorga R, et al. Cys 634 mutations in the RET proto-oncogene in Spanish families affected by MEN 2A. Hum Mutat. 1998;1:S72–3.PubMedCrossRef Sánchez B, Antiñolo G, Navarro E, Japón MA, Conde AF, Astorga R, et al. Cys 634 mutations in the RET proto-oncogene in Spanish families affected by MEN 2A. Hum Mutat. 1998;1:S72–3.PubMedCrossRef
8.
go back to reference Sanchez B, Robledo M, Biarnes J, Saez ME, Volpini V, Benitez J, et al. High prevalence of the C634Y mutation in the RET proto-oncogene in MEN 2A families in Spain. J Med Genet. 1999;36:68–70.PubMedPubMedCentral Sanchez B, Robledo M, Biarnes J, Saez ME, Volpini V, Benitez J, et al. High prevalence of the C634Y mutation in the RET proto-oncogene in MEN 2A families in Spain. J Med Genet. 1999;36:68–70.PubMedPubMedCentral
9.
go back to reference Puñales MK, Graf H, Gross JL, Maia AL. RET codon 634 mutations in multiple endocrine neoplasia type 2: variable clinical features and clinical outcome. J Clin Endocrinol Metab. 2003;88:2644–9.PubMedCrossRef Puñales MK, Graf H, Gross JL, Maia AL. RET codon 634 mutations in multiple endocrine neoplasia type 2: variable clinical features and clinical outcome. J Clin Endocrinol Metab. 2003;88:2644–9.PubMedCrossRef
10.
go back to reference Sakorafas GH, Friess H, Peros G. The genetic basis of hereditary medullary thyroid cancer: clinical implications for the surgeon, with a particular emphasis on the role of prophylactic thyroidectomy. Endocr Relat Cancer. 2008;15:871–84.PubMedCrossRef Sakorafas GH, Friess H, Peros G. The genetic basis of hereditary medullary thyroid cancer: clinical implications for the surgeon, with a particular emphasis on the role of prophylactic thyroidectomy. Endocr Relat Cancer. 2008;15:871–84.PubMedCrossRef
11.
go back to reference Sanso GE, Domene HM, Garcia R, Pusiol E, Roque M, Ring A, et al. Very early detection of RET proto-oncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia type 2 children: presence of C-cell malignant disease in asymptomatic carriers. Cancer. 2002;15(94):323–30.CrossRef Sanso GE, Domene HM, Garcia R, Pusiol E, Roque M, Ring A, et al. Very early detection of RET proto-oncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia type 2 children: presence of C-cell malignant disease in asymptomatic carriers. Cancer. 2002;15(94):323–30.CrossRef
12.
go back to reference Piolat C, Dyon JF, Sturm N, Pinson S, Bost M, Jouk PS, et al. Very early prophylactic thyroid surgery for infants with a mutation of the RET proto-oncogene at codon 634: evaluation of the implementation of international guidelines for MEN type 2 in a single centre. Clin Endocrinol. 2006;65:118–24.CrossRef Piolat C, Dyon JF, Sturm N, Pinson S, Bost M, Jouk PS, et al. Very early prophylactic thyroid surgery for infants with a mutation of the RET proto-oncogene at codon 634: evaluation of the implementation of international guidelines for MEN type 2 in a single centre. Clin Endocrinol. 2006;65:118–24.CrossRef
Metadata
Title
Genetic disorders of pediatric MEN2A patients in the south of Spain
Authors
Y. Martinez-Criado
R. M. Fernandez
S. Borrego
R. Cabello
I. Fernandez-Pineda
Publication date
01-11-2014
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 11/2014
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-014-1172-z

Other articles of this Issue 11/2014

Clinical and Translational Oncology 11/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine